World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
23685
World Ranking
17999
National Ranking
8972

Maurizio Zangari publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maurizio Zangari sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 455 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Maurizio Zangari D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maurizio Zangari sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Maurizio Zangari is affiliated with the University of Arkansas for Medical Sciences in the United States. Their research primarily focuses on hematology and oncology, with a particular emphasis on multiple myeloma. The scientist has contributed extensively to the medical literature, with published work spanning medicine, biochemistry, genetics, and molecular biology.

The main topics covered in their research include:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Lymphocytic Leukemia Research

Their work is published predominantly in several recurring journals, which present a pattern of specialized scientific communication. Frequent publication venues include:

  • Blood
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Cancer Journal

Zangari's research partnerships involve numerous coauthors with whom they have a significant collaborative footprint. Regular coauthors include Carolina Schinke, Frits van Rhee, Sharmilan Thanendrarajan, Samer Al Hadidi, and John D. Shaughnessy, reflecting a network of collaboration within the field of hematology and oncology.

The scientist has contributed to various studies covering molecular and clinical aspects of multiple myeloma. Notable recent papers include:

  • "The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma," 2021, Nature Communications
  • "Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis," 2023, Blood Advances
  • "Long-term outcomes after autologous stem cell transplantation for multiple myeloma," 2020, Blood Advances
  • "Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study," 2024, Blood Cancer Journal
  • "Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials," 2020, PLoS Medicine

Their body of work contributes to understanding the biological mechanisms underlying multiple myeloma progression and treatment response. This includes examining molecular pathways, clinical outcomes post-transplantation, infection risks with novel therapies, and bone marrow microenvironment influences.

Maurizio Zangari's publication record and collaborative network reflect an active engagement in advancing the knowledge and treatment approaches within hematology, particularly focused on multiple myeloma. Their cross-disciplinary impact spans medicine and molecular biology, integrating clinical insights with molecular research methods.

Best Publications

  • The molecular classification of multiple myeloma

    Fenghuang Zhan;Yongsheng Huang;Yongsheng Huang;Simona Colla;Simona Colla;James P. Stewart;James P. Stewart

  • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

    John D. Shaughnessy;Fenghuang Zhan;Bart E. Burington;Yongsheng Huang

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Thalidomide and hematopoietic-cell transplantation for multiple myeloma

    Bart Barlogie;Guido Tricot;Elias Anaissie;John Shaughnessy

  • Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

    Fenghuang Zhan;Johanna S. Hardin;Bob Kordsmeier;Klaus Bumm

  • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

    Bart Barlogie;Raman Desikan;Raman Desikan;Paul Eddlemon;Paul Eddlemon;Trey Spencer;Trey Spencer

  • Treatment of multiple myeloma

    Bart Barlogie;John D Shaughnessy;Guido Tricot;Joth Jacobson

  • Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

    Maurizio Zangari;Elias Anaissie;Bart Barlogie;Ashraf Badros

  • Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications

    Ronald Walker;Bart Barlogie;Jeffrey Haessler;Guido Tricot

  • Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

    Fenghuang Zhan;Bart Barlogie;Varant Arzoumanian;Yongsheng Huang

  • Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

    Raman Desikan;Bart Barlogie;Bart Barlogie;Jeffrey Sawyer;Jeffrey Sawyer;Dan Ayers;Dan Ayers

  • Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

    Bart Barlogie;Elias Anaissie;Frits Van Rhee;Jeffrey Haessler

  • Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    L. Rasche;S. S. Chavan;O. W. Stephens;P. H. Patel

  • Results of autologous stem cell transplant in multiple myeloma patients with renal failure.

    Ashraf Badros;Bart Barlogie;Eric Siegel;Jennifer Roberts

  • Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

    Maurizio Zangari;Eric Siegel;Bart Barlogie;Elias Anaissie

  • Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

    Maurizio Zangari;Bart Barlogie;Elias Anaissie;Fariba Saghafifar

  • NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

    Wen Zhou;Ye Yang;Ye Yang;Jiliang Xia;Jiliang Xia;He Wang;He Wang

  • Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

    Bart Barlogie;Mauricio Pineda-Roman;Frits van Rhee;Jeff Haessler

  • Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.

    Ashraf Badros;Bart Barlogie;Eric Siegel;Christopher Morris

  • ORIGINAL ARTICLE Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A Palumbo;SV Rajkumar;MA Dimopoulos;PG Richardson

Frequent Co-Authors

Frits van Rhee
Frits van Rhee University of Arkansas for Medical Sciences
Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Gareth J. Morgan
Gareth J. Morgan Boston University
Guido Tricot
Guido Tricot University of Iowa
Faith E. Davies
Faith E. Davies New York University Langone Medical Center
Joshua Epstein
Joshua Epstein University of Arkansas for Medical Sciences
Elias Anaissie
Elias Anaissie University of Cincinnati
Brian A Walker
Brian A Walker Indiana University – Purdue University Indianapolis
John D. Shaughnessy
John D. Shaughnessy University of Arkansas for Medical Sciences
John Crowley
John Crowley Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open valuable career options in healthcare beyond traditional medical studies. For students interested in patient care but looking for more accessible entry, consider nursing schools that don't require teas. These programs remove some standardized testing barriers, making the path to a nursing career more attainable.

If you’re drawn to the organizational side of healthcare, there are reputable online health administration programs that offer flexibility alongside a fast-track to leadership roles in hospitals, clinics, and insurance companies.

Registered nurses considering career advancement should look into RN to NP programs online. These bridge programs allow RNs to become nurse practitioners, expanding their scope of practice and opening doors to higher-level positions.

Alternatively, those passionate about diet and wellness may wish to explore an online BS in nutrition, preparing for diverse roles in healthcare, community wellness, and research.

Best Scientists Citing Maurizio Zangari

Trending Scientists

Recently Published Articles